This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 717482
Download Presentation The PPT/PDF document "Relapsed/Refractory Follicular Lymphoma ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Relapsed/Refractory Follicular Lymphoma ConundrumsSlide2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide3
Epidemiology of FLSlide4
Presentation TopicsSlide5
Recommended Frontline Therapies for FLSlide6
Considerations in Selecting Therapy for R/R FLSlide7
Recommended Second-Line Therapies for FLSlide8
Management Challenges in R/R FLSlide9
Strategies for Selecting Therapy for R/R FLSlide10
Novel TherapiesSlide11
Copanlisib Slide12
CHRONOS-1 Trial of Copanlisib
Methods Slide13
CHRONOS-1 Trial of CopanlisibEfficacySlide14
CHRONOS-1 Trial of Copanlisib
SafetySlide15
Idelalisib Slide16
Phase 2 Trial of Idelalisib Monotherapy in R/R FL
Design and Efficacy Slide17
Phase 2 Trial of Idelalisib Monotherapy in R/R FL
Safety Slide18
DuvelisibSlide19
DYNAMO Trial of DuvelisibSlide20
MAGNIFY Trial of Rituximab + Lenalidomide Design
Slide21
MAGNIFY TrialResponseSlide22
MAGNIFY TrialPFSSlide23
MAGNIFY TrialSafetySlide24
Additional Trials of R + LenalidomideSlide25
Obinutuzumab Slide26
GADOLIN TrialDesignSlide27
GADOLIN Trial
EfficacySlide28
GADOLIN TrialSafetySlide29
Incorporating New Agents Into Treatment Paradigm
ChallengesSlide30
Incorporating New Agents Into Treatment Paradigm
SelectionSlide31
Current Knowledge About Novel AgentsSlide32
Ongoing Trials in R/R FLSlide33
AbbreviationsSlide34
Abbreviations (cont)